Anti-Tissue Plasminogen Activator antibody (ab48649)
Key features and details
- Sheep polyclonal to Tissue Plasminogen Activator
- Suitable for: ELISA, EIA, IP, RIA, WB
- Reacts with: Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-Tissue Plasminogen Activator antibody
See all Tissue Plasminogen Activator primary antibodies -
Description
Sheep polyclonal to Tissue Plasminogen Activator -
Host species
Sheep -
Tested applications
Suitable for: ELISA, EIA, IP, RIA, WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Human TPA Tissue Plasminogen Activator purified from human plasma.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.50
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: PBS, 50% Glycerol -
Concentration information loading...
-
Purity
Protein G purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab48649 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
EIA |
Use at an assay dependent concentration.
|
|
IP |
Use at an assay dependent concentration.
|
|
RIA |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration.
|
Notes |
---|
ELISA
Use at an assay dependent concentration. |
EIA
Use at an assay dependent concentration. |
IP
Use at an assay dependent concentration. |
RIA
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
Target
-
Function
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration. -
Tissue specificity
Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk. -
Involvement in disease
Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism. -
Sequence similarities
Belongs to the peptidase S1 family.
Contains 1 EGF-like domain.
Contains 1 fibronectin type-I domain.
Contains 2 kringle domains.
Contains 1 peptidase S1 domain. -
Domain
Both FN1 and one of the kringle domains are required for binding to fibrin.
Both FN1 and EGF-like domains are important for binding to LRP1.
The FN1 domain mediates binding to annexin A2.
The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site. -
Post-translational
modificationsThe single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.
Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.
N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.
Characterization of O-linked glycan was studied in Bowes melanoma cell line. -
Cellular localization
Secreted > extracellular space. - Information by UniProt
-
Database links
- Entrez Gene: 5327 Human
- Omim: 173370 Human
- SwissProt: P00750 Human
- Unigene: 491582 Human
-
Alternative names
- Alteplase antibody
- DKFZp686I03148 antibody
- Plasminogen activator tissue antibody
see all
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab48649 has not yet been referenced specifically in any publications.